ClearNote Health targets early pancreatic cancer detection with multi-analyte blood test data
ClearNote Health will present Avantect pancreatic cancer test validation data at ASCO 2026. Find out what it could mean for early detection.
Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance
MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.
Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
Read how SAGA Diagnostics’ AACR 2026 Pathlight data could reshape ctDNA monitoring in metastatic breast and ovarian cancer.
Can Junction’s GRAIL tie-up do what clinical data alone could not for Galleri adoption?
Junction and GRAIL are expanding Galleri access, but can workflow integration overcome regulatory, reimbursement, and adoption hurdles? Read more.
Why PanGIA Biotech’s urine biopsy data may matter more than the headline sensitivity figure suggests
PanGIA Biotech reported 97.8% sensitivity in a urine-based prostate cancer study. Read what the data changes and what risks still remain.
How Exact Sciences is building a multi-platform cancer diagnostics case at AACR 2026
Exact Sciences presents Oncodetect MRD and Cancerguard MCED data at AACR 2026. Analysis of what the new TNBC and multi-biomarker classifier findings mean for clinical adoption.
Guardant Health brings Shield multi-cancer detection test to Asia through Manulife insurer deal
Guardant Health partners with Manulife to launch its Shield MCD blood test in Hong Kong, Singapore and the Philippines. Analysis of what this means for oncology.
Pillar Biosciences launches rapid AML sequencing panel while Creatv Bio liquid biopsy enters colorectal cancer trial biomarker role
Pillar Biosciences launches rapid AML sequencing panel as Creatv Bio liquid biopsy enters colorectal cancer trial. Explore what these tools mean for oncology research.
How Creatv Bio’s LifeTracDx may change immune biomarker tracking in colorectal cancer studies
Creatv Bio’s LifeTracDx joins CytoDyn’s Phase 2 colorectal cancer trial as a liquid biopsy biomarker tool. Discover what this means for oncology diagnostics.